Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. (1st April 2017)

• Record Type: Journal Article
• Authors: Han, Shuanglin; Latchoumanin, Olivier; Wu, Guang; Zhou, Gang; Hebbard, Lionel; George, Jacob; Qiao, Liang
• Is Part Of: Cancer letters. Volume 390(2017)
• Page Start: 188
• Page End: 200
• Publication Date: 2017-04-01
• Subjects: Chimeric antigen receptor -- Modified T cells -- Solid tumor -- Clinical trials -- Immunotherapy; AML acute myeloid leukemia -- APCs antigen-presenting cells -- CAR chimeric antigen receptor -- CTLA-4 cytotoxic-T-lymphocyte antigen 4 -- CTLs cytotoxic T lymphocytes -- DCs dendritic cells -- ESCs embryonic stem cells -- MHC major histocompatibility complex -- PD-1 programmed cell death protein 1 -- scFv single chain variable fragment -- TCRs T cell receptors; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2016.12.037
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Chimeric antigen receptors (CARs) are a series of manufactured receptors that have the capacity of binding to specific antigens expressed on surface of tumor cells. A CAR normally has an extracellular antigen recognition domain derived from single variable chain of a monoclonal antibody, a transmembrane domain and an intracellular T cell activation domain. During the last decade, CAR-T cells were demonstrated to possess great therapeutic effects on hematological malignancies. However, strategies using CAR-T cells to treat solid tumors have been hindered by considerable obstacles including "on tissue off target" effects and cytokine storm syndrome. This review will summarize the current understanding of CAR-T cell therapies and briefly describe the currently enrolled clinical trials in solid tumors. Highlights: Many clinical trials have demonstrated a great potential of CAR-T cell therapy for hematologic malignancies. Use of CAR-T cell therapies for solid tumors has been hindered by lack of specific tumor antigen. This paper summarizes the current understanding of CAR-T cell therapies for solid tumors.